Advancing Safety Analytics

This initiative aims to develop best practices and guidance around the application of interrogative methods towards various safety data sources. As of December 2021, this initiative is now complete. No new solutions or updates are planned.

Rationale

The power of analytics is enabling the pharmaceutical industry to improve insights on drug safety to strengthen patient care at large.  But limited data exists on the effectiveness of these various methodologies. In addition, there is an opportunity to identify new data sources and / or novel methodologies which could drive further understanding of product profiles and support product development. This initiative aims to develop best practices and guidance around the application of interrogative methods towards various safety data sources.

Benefits

  • Earlier identification of potential safety issues to help minimize harm to patients
  • Improved quality data analytics and verified methodologies could enable a more informed product development outcome
  • Accelerated method development and sharing of best practices through collaboration and piloting

Available Solutions

Related Initiatives

Value of Safety Information Data Sources

The Value of Safety Information Data Sources Initiative will seek to identify sources of safety information for single high value valid cases and develop a proposed method for aggregate reporting of lower value cases.